Case Name: DURAMED PHARMACEUTICALS, INC., Plaintiff-Appellant, v. WATSON LABORATORIES, INC., Defendant-Appellee
Court: United States Court of Appeals for the Federal Circuit
Jurisdiction: United States
Decision Date: 2011-06-17
Citations: 425 F. App'x 895
Docket Number: No. 2011-1438
Parties: DURAMED PHARMACEUTICALS, INC., Plaintiff-Appellant, v. WATSON LABORATORIES, INC., Defendant-Appellee.
Judges: 
Reporter: West's Federal Appendix
Volume: 425
Pages: 895–896

Head Matter:
DURAMED PHARMACEUTICALS, INC., Plaintiff-Appellant, v. WATSON LABORATORIES, INC., Defendant-Appellee.
No. 2011-1438.
United States Court of Appeals, Federal Circuit.
June 17, 2011.
Vernon M. Winters, Greenberg Traurig LLP, San Francisco, CA, for Plaintiff-Appellant.
Cedric C.Y. Tan, Kilpatrick Townsend & Stockton LLP, Washington, DC, for Defendant-Appellee.
Before NEWMAN, Circuit Judge.

Opinion:
ON MOTION
ORDER
Duramed Pharmaceuticals, Inc. (Du-ramed) submits a motion for an injunction to prevent Watson Laboratories, Inc. (Watson) from launching a generic version of its patented drug, pending disposition of its appeal. Duramed also requests a temporary injunction, pending disposition of this motion.
Upon consideration thereof,
It Is Ordered That:
(1) Watson is directed to respond to the motion no later than July 1,2011.
(2) Watson is temporarily enjoined from launching its generic, pending this court's receipt of the response and the court's consideration of the papers submitted.